13F Holdings
中文EN

BVS Bioventus Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1665988 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.9%
TTM net income YoY655.0%
TTM EPS YoY575.0%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin68.7%
Operating margin9.7%
Net margin9.8%
FCF margin14.5%
EBITDA margin14.0%

Returns

ROE28.2%
ROA8.3%
ROIC (approx.)12.8%
Asset turnover0.85x

Leverage & solvency

Liabilities / assets56.7%
Debt / equity0.96x
Current ratio1.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.53x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$568.09M$573.28M$512.35M$512.12M$430.90M
Cost of revenue$179.93M$185.05M$184.15M$181.04M$128.19M
Gross profit$388.16M$388.23M$328.19M$331.08M$302.71M
R&D expense$12.11M$13.95M$13.45M$23.85M$19.04M
SG&A expense$314.03M$343.80M$303.88M$332.13M$254.25M
Operating income$53.98M-$15.20M-$81.72M-$167.23M$12.06M
Pretax income$25.71M-$52.34M-$121.11M-$189.03M$9.49M
Income tax-$1.56M-$5.29M$85,000-$44.37M-$1.97M
Net income$22.73M-$36.12M-$156.23M-$158.70M$19.38M
EBITDA$100.99M$34.36M-$24.36M-$111.84M$46.94M
EPS (basic)0.34-0.56-2.49-2.59-0.15
EPS (diluted)0.33-0.56-2.49-2.59-0.15
Weighted avg. shares (diluted)68.91M64.55M62.65M61.39M45.47M
Balance sheet
Cash & equivalents$51.24M$41.58M$36.96M$31.84M$99.21M
Receivables$128.30M$127.39M$122.79M$136.29M$124.96M
Inventory$82.24M$92.47M$91.33M$84.77M$61.69M
Current assets$272.84M$275.61M$268.00M$272.57M$263.10M
PP&E, net$21.90M$27.01M$36.60M$27.46M$22.98M
Goodwill$7.46M$7.46M$7.46M$7.46M$147.62M
Intangibles$368.42M$404.73M$482.35M$639.85M$695.19M
Total assets$683.56M$727.96M$810.91M$1.37B$1.23B
Current liabilities$160.38M$210.40M$175.50M$304.02M$180.86M
Short-term debt$15.00M$27.34M$27.85M$33.06M$18.04M
Long-term debt$278.95M$308.29M$367.00M$385.01M$339.64M
Total debt$293.95M$335.63M$394.85M$418.07M$357.68M
Total liabilities$455.11M$542.35M$589.79M$960.43M$618.21M
Shareholders' equity$184.10M$147.94M$173.59M$325.24M$458.92M
Net debt$242.71M$294.05M$357.88M$386.23M$258.47M
Cash flow statement
Operating cash flow$74.67M$38.80M$15.34M-$13.54M$22.99M
Capital expenditure$2.56M$1.01M$7.36M$1.48M$13.52M
Free cash flow$72.11M$37.79M$7.98M-$15.02M$9.47M
Investing cash flow-$3.25M$22.96M$15.81M-$116.44M-$283.76M
Financing cash flow-$62.14M-$54.58M-$26.65M$62.08M$273.37M
Depreciation & amortization$47.01M$49.55M$57.37M$55.40M$34.88M
Stock-based compensation$12.67M$13.27M$2.72M$17.59M$19.84M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.